Danford Christopher, Chan Pennapa, Magill Steven B
WMJ. 2016 Aug;115(4):206-9.
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, one of a class of novel antiglycemic agents that are gaining in popularity in the treatment of diabetes.
We describe a case in which a patient experienced difficult-to-treat metabolic ketoacidosis in the setting of canagliflozin use.
A 52-year-old man with type 2 diabetes mellitus developed profound ketoacidosis without overt hyperglycemia while taking canagliflozin. Despite initiation of an insulin infusion, the metabolic acidosis persisted for 3 days.
Treatment with canagliflozin was associated with development of euglycemic ketoacidosis.
卡格列净是一种钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂，是一类新型抗糖尿病药物，在糖尿病治疗中越来越受欢迎。
我们描述了一例在使用卡格列净的情况下发生难以治疗的代谢性酮症酸中毒的病例。
一名52岁的2型糖尿病男性在服用卡格列净时出现了严重的酮症酸中毒，且无明显高血糖。尽管开始输注胰岛素，但代谢性酸中毒仍持续了3天。
卡格列净治疗与正常血糖性酮症酸中毒的发生有关。
